Novavax posted a fiscal fourth-quarter loss that’s wider than anticipated by analysts. However, the vaccine development company’s revenue came in higher than expected.
The net loss for the quarter widened to -$2.70 a share from -$1.13 in the year-earlier quarter. FactSet poll shows consensus estimates of a GAAP net loss of -$2.23 a share
Revenue rose $279.7 million from $8.8 million. That's higher than analysts' forecast of $202.4 million. The increase in revenue can be attributed to the company's services under an agreement with CEPI, which raises money for and supports vaccine development, and services to the U.S. government's Operation Warp Speed vaccine-development program.
"With positive efficacy results, including against evolving variant strains, NVX-Cov2373 offers a highly unique profile, including the ability to ship and store the vaccine at traditional refrigerated temperatures," President and CEO Stanley Erck said in a statement.
These attributes, according to Erck , should support emergency-use authorization. The company has initiated talks with regulators to pursue appropriate regulatory authorization, Erck indicated.
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The 10-day moving average for NVAX crossed bearishly below the 50-day moving average on April 05, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NVAX broke above its upper Bollinger Band on May 01, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NVAX entered a downward trend on April 29, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on April 29, 2024. You may want to consider a long position or call options on NVAX as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NVAX just turned positive on April 26, 2024. Looking at past instances where NVAX's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
NVAX moved above its 50-day moving average on May 03, 2024 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (10.284). P/E Ratio (0.000) is within average values for comparable stocks, (116.129). NVAX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.466). NVAX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (0.893) is also within normal values, averaging (233.049).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company which engages in development of novel recombinant vaccines
Industry Biotechnology